13404-22-3

Basic information

• Product Name: tert-Butyl L-alaninate hydrochloride
• Synonyms: ALANINE-OTBU HCL;L-ALANINE T-BUTYL ESTER HYDROCHLORIDE;L-ALANINE T-BUTYL ESTER HYDROCHLORIDE SALT;L-ALANINE TERT-BUTYL ESTER HYDROCHLORIDE;L-ALA-T-BUTYL ESTER HCL;H-ALA-OBUT HCL;H-ALA-OTBU HCL;H-ALA-OTBU HYDROCHLORIDE
• CAS NO: 13404-22-3
• Molecular Formula: C₇H₁₅NO₂*ClH
• Molecular Weight: 181.66
• EINECS: 236-497-8
• Product Categories: Amino Acids Derivatives;Amino Acids;Alanine [Ala, A];Amino Acids and Derivatives;Amino Acid tert-Butyl Esters;Amino Acids (C-Protected);Biochemistry;Amino hydrochloride;A - HPeptide Synthesis;Alanine;Amino Acid Derivatives;Amino Acids;Modified Amino Acids;Peptide Synthesis;amino
• Mol File: 13404-22-3.mol
• Article Data: 5

Chemical Properties

• Melting Point: 168-175 °C (dec.)
• Boiling Point: 163.1 °C at 760 mmHg
• Flash Point: 37 °C
• Appearance: White to off-white/Solid or Crystalline Powder
• Vapor Pressure: 2.1mmHg at 25°C
• Refractive Index: 2.0 ° (C=2, EtOH)
• Storage Temp.: 2-8°C
• Solubility: Soluble in methanol.
• Sensitive: Hygroscopic
• BRN: 3562140
• CAS DataBase Reference: tert-Butyl L-alaninate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl L-alaninate hydrochloride(13404-22-3)
• EPA Substance Registry System: tert-Butyl L-alaninate hydrochloride(13404-22-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 22-24/25-36-26
• WGK Germany: 3
• Hazardous Substances Data: 13404-22-3(Hazardous Substances Data)

Usage

Chemical Properties

Crystalline powder

Uses

It is used as a pharmaceutical intermediate.

InChI:InChI=1/C7H15NO2.ClH/c1-5(8)6(9)10-7(2,3)4;/h5H,8H2,1-4H3;1H/t5-;/m0./s1

Upstream product

• 58177-77-8 N-[(1,1-dimethylethoxy)carbonyl]-L-alanine 1,1-dimethylethyl ester 
• 540-88-5 acetic acid tert-butyl ester 
• 56-41-7 L-alanin 
• 50300-96-4 (S)-2-(benzyloxycarbonylamino)propionic acid tert-butyl ester 

Downstream Products

• 80828-28-0 N-<(R)-1-(ethoxycarbonyl)-3-phenylpropyl>-L-alanine tert-butylester 
• 80828-38-2 N-<(S)-1-(ethoxycarbonyl)-3-phenylpropyl>-L-alanine tert-butylester 
• 92779-28-7 Z-Ile-Ala-O-t-Bu 
• 58177-77-8 N-[(1,1-dimethylethoxy)carbonyl]-L-alanine 1,1-dimethylethyl ester 
• 849919-50-2 2-benzyl-2-(1-tert-butoxycarbonyl-ethylcarbamoyl)-azetidine-1-carboxylic acid benzyl ester 
• 97391-52-1 Z-Asn-Ile-Ala-O-t-Bu 
• 97391-53-2 Z-Asn-Asn-Ile-Ala-O-t-Bu 
• 98694-99-6 H-Phe-Ala-O-t-Bu*CH₃COOH 
• 92954-74-0 N-Carbobenzoxy-O-tert-butyl-L-seryl-L-asparaginyl-L-alanine tert-butyl ester 
• 92954-75-1 N-Carbobenzoxy-O-tert-butyl-L-seryl-O-tert-butyl-L-seryl-L-asparaginyl-L-alanine tert-butyl ester 
• 383662-05-3 tert-butyl (2R)-2-[[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]aminopropionate 
• 21691-50-9 Ala-OtBu 
• 959628-20-7 (S)-tert-butyl 2-((2R,3S)-3-hydroxy-2-methyl-3-phenylpropanamido)propanoate 
• 959628-15-0 (2S)-tert-butyl 2-(2-chloro-3-phenylpropanamido)propanoate 

Relevant articles and documents

Cyclic phosphoramidates as prodrugs of 2′-C-methylcytidine

The currently approved treatment for hepatitis C virus infections is a combination of Ribavirin and pegylated Interferon. It leads to a sustained virologic response in approximately only half of the patients treated. For this reason there is an urgent need of new therapeutic agents. 2′-C-Methylcytidine is the first nucleoside inhibitor of the HCV NS5B polymerase that was efficacious in reducing the viral load in patients infected with HCV. The application of a monophosphate prodrug approach based on unprecedented cyclic phosphoramidates is reported. Our SAR studies led to compounds that are efficiently converted to the active triphosphate in human hepatocytes.

Synthesis of optically active lipopeptide analogs from the outer membrane of Escherichia coli

The synthesis of optically active lipopeptide derivatives has been accomplished by the use of chiral glycerol derivatives. Lipopeptide derivatives with (R)-glycerol moieties showed higher mitogenic activities than those with the (S)-configuration. N-2,2,2-Trichloroethoxycarbonyl lipopeptide derivatives increased mitogenic activity.

Carboxyalkyl amino acid derivatives of various substituted prolines

-